S 237648

Drug Profile

S 237648

Alternative Names: S-237648

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Class Obesity therapies
  • Mechanism of Action Neuropeptide Y5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity

Most Recent Events

  • 27 Sep 2016 Shionogi completes a phase II trial in Obesity in Japan (PO) (JapicCTI-153001)
  • 02 Sep 2015 Phase-II clinical trials in Obesity in Japan (PO) (JapicCTI-153001)
  • 03 Feb 2014 Phase-I clinical trials in Obesity in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top